Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05733611

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

MSS Clinical Trial

Official title:
A Phase 2 Clinical Trial Investigating Oncolytic Immunotherapy in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With Advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma

Clinical Trial Summary

This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma.

Clinical Trial Description

RP2 and RP3 are selectively replication competent herpes simplex viruses 1 (HSV-1) that express exogenous genes (RP2: GM-CSF, GALV, and anti-CTLA-4; RP3: GALV, and anti-CTLA-4 hCD40L, and h4-1BBL) intended for direct injection into suitable nonneurological solid tumors. They are genetically engineered to provide direct oncolytic tumor destruction combined with the induction of a systemic antitumor immune response. This study will evaluate whether the use of oncolytic immunotherapy, either with RP2 or RP3, can provide meaningful efficacy in combination with an anti-PD-L1 therapy (atezolizumab) and anti-VEGF therapy (bevacizumab) in patients with advanced MSS and pMMR CRC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05733611
Study type Interventional
Source Replimune Inc.
Contact
Status Active, not recruiting
Phase Phase 2
Start date June 29, 2023
Completion date March 1, 2027
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04527068 - QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer Phase 2
Recruiting NCT04659382 - Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer Phase 2
Completed NCT03271047 - Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation Phase 2
Recruiting NCT05815303 - XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer Phase 2
Recruiting NCT06321081 - ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC Phase 2
Recruiting NCT04483219 - Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. Phase 2
Active, not recruiting NCT04046445 - Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer Phase 1
Recruiting NCT04030260 - Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer Phase 2
Recruiting NCT05877573 - Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer N/A
Recruiting NCT06199232 - Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment N/A
Recruiting NCT05731726 - Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer Phase 2
Recruiting NCT05933980 - Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer Phase 2
Completed NCT03274804 - Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC Phase 1